Ignite Creation Date:
2024-05-06 @ 6:44 PM
Last Modification Date:
2024-10-26 @ 2:53 PM
Study NCT ID:
NCT05765851
Status:
RECRUITING
Last Update Posted:
2024-04-30
First Post:
2023-03-01
Brief Title:
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
Sponsor:
Daiichi Sankyo
Organization:
Daiichi Sankyo
Study Overview
Official Title:
A Phase 1 2-Part Multicenter First-In-Human Dose-Escalation and Dose-Expansion Study of DS-1103a Combination Therapy in Subjects With Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety and efficacy of DS-1103a combination therapy in patients with advanced solid tumors
Detailed Description:
DS-1103a a recombinant humanized IgG4 anti-SIRPĪ± antibody designed to block the SIRPĪ±-CD47 interaction is being developed for the treatment of advanced cancers in combination with other anticancer therapies This is the first-in-human dose-escalating clinical study designed to assess the safety and efficacy of DS-1103a combination therapy in patients with advanced solid tumors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-503965-48-00 | OTHER | EU CT | None |